Literature DB >> 2502800

Systemic injection of pirenzepine induces a deficit in passive avoidance learning in rats.

P Worms1, C Gueudet, A Pério, P Soubrié.   

Abstract

When injected IP, the M1 muscarinic receptor antagonist pirenzepine dose-dependently induced a deficit in passive avoidance learning in rats. This activity was optimal at 75 mg/kg injected 1 h before the acquisition session. The deficit induced by pirenzepine was antagonized by oxotremorine (0.03-0.3 mg/kg SC) and physostigmine (0.1 mg/kg SC), but not neostigmine. By comparison, under the same experimental conditions, physostigmine and oxotremorine also antagonized the deficit induced by an equipotent dose of scopolamine (0.5 mg/kg IP), although the activity of physostigmine appeared stronger against scopolamine than against pirenzepine. These results suggest that pirenzepine could produce a centrally-mediated behavioural disruption when injected systemically.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502800     DOI: 10.1007/bf00444707

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  11 in total

1.  An evaluation of the mechanism of scopolamine-induced impairment in two passive avoidance protocols.

Authors:  K Elrod; J J Buccafusco
Journal:  Pharmacol Biochem Behav       Date:  1988-01       Impact factor: 3.533

2.  The pharmacokinetic profile of pirenzepine.

Authors:  R Hammer; F W Koss
Journal:  Scand J Gastroenterol Suppl       Date:  1979

3.  Central administration of the muscarinic receptor subtype-selective antagonist pirenzepine selectively impairs passive avoidance learning in the mouse.

Authors:  M P Caulfield; G A Higgins; D W Straughan
Journal:  J Pharm Pharmacol       Date:  1983-02       Impact factor: 3.765

4.  Central oxotremorine antagonist properties of pirenzepine.

Authors:  J M Witkin; R Alvarado-Garcia; L A Perez; K M Witkin
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

5.  The effect of pirenzepine on spatial learning in the Morris Water Maze.

Authors:  A J Hunter; F F Roberts
Journal:  Pharmacol Biochem Behav       Date:  1988-06       Impact factor: 3.533

6.  The effects of anticholinergics on the photopalpebral reflex, memory and mood.

Authors:  L Walters; P Bartel; D K Sommers; P Becker
Journal:  Methods Find Exp Clin Pharmacol       Date:  1988-07

7.  Pirenzepine distinguishes between different subclasses of muscarinic receptors.

Authors:  R Hammer; C P Berrie; N J Birdsall; A S Burgen; E C Hulme
Journal:  Nature       Date:  1980-01-03       Impact factor: 49.962

Review 8.  Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases.

Authors:  A A Carmine; R N Brogden
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

9.  Comparison of in vitro actions with behavioral effects of antimuscarinic agents.

Authors:  J M Witkin; R K Gordon; P K Chiang
Journal:  J Pharmacol Exp Ther       Date:  1987-09       Impact factor: 4.030

10.  Antagonism by cholinomimetic drugs of the turning induced by intrastriatal pirenzepine in mice.

Authors:  P Worms; K Biziere
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

View more
  5 in total

1.  Effects of the selective M1 muscarinic receptor antagonist dicyclomine on emotional memory.

Authors:  R V Fornari; K M Moreira; M G Oliveira
Journal:  Learn Mem       Date:  2000 Sep-Oct       Impact factor: 2.460

2.  The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide.

Authors:  Surabi Veeraragavan; Nghiem Bui; Jennie R Perkins; Lisa A Yuva-Paylor; Richard Paylor
Journal:  Behav Neurosci       Date:  2011-10       Impact factor: 1.912

3.  Modulation of behavioral phenotypes by a muscarinic M1 antagonist in a mouse model of fragile X syndrome.

Authors:  Surabi Veeraragavan; Nghiem Bui; Jennie R Perkins; Lisa A Yuva-Paylor; Randall L Carpenter; Richard Paylor
Journal:  Psychopharmacology (Berl)       Date:  2011-04-13       Impact factor: 4.530

4.  SR 46559A: a novel and potent muscarinic compound with no cholinergic syndrome.

Authors:  J P Kan; R Steinberg; F Oury-Donat; J C Michaud; O Thurneyssen; J P Terranova; C Gueudet; J Souilhac; R Brodin; R Boigegrain
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Moringa oleifera Seed Extract Alleviates Scopolamine-Induced Learning and Memory Impairment in Mice.

Authors:  Juan Zhou; Wu-Shuang Yang; Da-Qin Suo; Ying Li; Lu Peng; Lan-Xi Xu; Kai-Yue Zeng; Tong Ren; Ying Wang; Yu Zhou; Yun Zhao; Li-Chao Yang; Xin Jin
Journal:  Front Pharmacol       Date:  2018-04-24       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.